Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Zahn

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of the American Academy of Dermatology|January 24, 2025
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, et al.
The Journal of Dermatological Treatment|March 11, 2026
Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularisBrian S Kim, Shawn G Kwatra, Gil Yosipovitch, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2025
Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumabElena Goleva, Evgeny Berdyshev, Simion Kreimer, et al.
BMC Medical Genomics|May 4, 2019
Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infectionMark H Kaplan, Mark Kaminski, Judith M Estes, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2026
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitisMichael J Cork, Peck Y Ong, Simon G Danby, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of the American Academy of Dermatology|January 24, 2025
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)Robert Bissonnette, Elena Goleva, Evgeny Berdyshev, et al.
The Journal of Dermatological Treatment|March 11, 2026
Dupilumab subgroup responder analysis: a <i>post hoc</i> analysis from LIBERTY PRIME and PRIME2 in prurigo nodularisBrian S Kim, Shawn G Kwatra, Gil Yosipovitch, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2025
Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumabElena Goleva, Evgeny Berdyshev, Simion Kreimer, et al.
BMC Medical Genomics|May 4, 2019
Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infectionMark H Kaplan, Mark Kaminski, Judith M Estes, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2026
Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitisMichael J Cork, Peck Y Ong, Simon G Danby, et al.
Pageof 3